Antiviral agents for non-human immunodeficiency virus infections

Mayo Clinic Proceedings

Volumn 74, Issue 12, 1999, Pages 1266-1283

  Keating, Michael R ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RIMANTADINE; VALACICLOVIR;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; VIRUS REPLICATION;

EID: 0032754441     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.12.1266     Document Type: Conference Paper

References (104)

1. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later [published errata appear in N Engl J Med 1993;328:671 and 1997;337:1703J. N EnglJMed 1992;327:782-789
2. Derse D, Cheng Y-C, Furman PA, St. Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)-guanine triphosphate: effects on primer-template function. J Biol Chem 1981:256:11447-11451
3. Keller PM, Fyfe JA, Beauchamp L, Lubbers CM, Furman PA, Schaeffer HJ, et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981:30:3071-3077
4. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, et al. 9-{[2-Hydroxy-l-(hydroxymethyl)ethoxy]-methyl}guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sei USA 1983:80:4139-4143
5. St. Clair MH, Miller WH, Miller RL, Lambe CU, Furman PA. Inhibition of cellular a DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U. Antimicrob Agents Chemother 1984:25:191-194
6. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997;31:185-191
7. Cirelll R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996:29:141-
8. 151
9. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996;31:l-8
10. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999:36:4166
11. Prusoff WH, Zucker M, Manclni WR, Otto MJ, Lin TS, Lee JJ. Basic biochemical and pharmacological aspects of antiviral agents. Antiviral Res Suppl 1985:1:1-10
12. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986:30:201-205
13. Ciampor F, Thompson CA, Grambas S, Hay AJ. Regulation of pH by the M2 protein of influenza A viruses. Virus Res 1992:22:247258
14. Hayden FG. Update on influenza and rhinovirus infections. Adv Exp Med Biol 1999:458:55-67
15. Wade JC, Hlntz M, McGuffin RW, Springmeyer SC, Connor JO, Meyers JD. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 1982;73(Suppl):249-256
16. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985:151:362-364
17. Nllsen AE, Aasen T, Halsos AM, Kinge BR, Tjetta EAL, Wikström K, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982:2:571-573
18. Relchman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984:251:21032107
19. Luby JP, Gnann JW Jr, Alexander WJ, Hatcher VA, Friedman-Kien AE, Klein RJ, et al. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis 1984;150:l-6
20. Corey L, Fife KH, Benedetti JK, Winter CA, Fahnlander A, Connor JD, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983:98:914-921
21. Straus SE, Croen KD, Sawyer MH, Freifeld AG, Felser JM, Dale JK, et al. Acyclovir suppression of frequently recurring genital herpes: efficacy and diminishing need during successive years of treatment. JAMA 1988:260:2227-2230
22. VanLandlngham KE, Marsteller HB, ROSS GW, Hayden FG. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA 1988:259:1051-1053
23. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, et al (National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group). A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991:324:444-449
24. Whitley RJ, Nahmias AJ, Soong S-J, Galasso GG, Fleming CL, Alford CA. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980;66:495-501
25. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987:31:361-367
26. Balfour HH Jr, Bean B, Laskin ÖL, Ambinder RF, Meyers JD, Wade JC, et al (Burroughs Wellcome Collaborative Acyclovir Study Group). Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983:308:1448-1453
27. Balfour HH Jr. Intravenous acyclovir therapy for varicella in immunocompromised children. J Pediatr 1984:104:134-136
28. Cobo M. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir. Am J Med 1988:85(Suppl 2A):90-93
29. Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85(Suppl 2A):84-89
30. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-347
31. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, England JA, Crane DD, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990:116:633-639
32. Wallace MR, Bowler WA, Murray NB, Brodlne SK, Oldfield EC III. Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann Intern Med 1992:117:358-363
33. Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990: 12:788-798
34. Cohen Jl, Brunei! PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999:130:922-932
35. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984:100:823-828
36. Seale L, Jones CJ, Kathpalia S, Jackson GG, Mozes M, Maddux MS, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985;254:3435-3438
37. Resnick L, Herbst JS, Ablashi DV, Atherton S, Frank B, Rosen L, et al. Régression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 1988:259:384-388
38. Andersson J, Britton S, Ernberg l, Andersson U, Henle W, Sköldenberg B, et al. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis 1986; 153:283-290
39. Straus SE, Dale JK, Tobi M, Lawley T, Preble 0, Blaese RM, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. N Engl J Med 1988:319:1692-1698
40. Beutner KR, Friedman DJ, Forszpanlak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995:39:1546-1553
41. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K (Valaciclovir HSV Study Group). A large-scale, placebo-controlled, dose-ranging trial of peroral Valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996:156:17291735
42. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al (International Valaciclovir HSV Study Group). Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998:178:603610
43. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al (International Valacyclovir Cytomegalovlrus Prophylaxis Transplantation Study Group). Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. W Engl J Med 1999:340:1462-1470
44. Frank KB, Chiou J-F, Cheng Y. Interaction of herpes simplex virusinduced DNA polymerase with 9-(l,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem 1984:259:1566-1569
45. Höchster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS clinical trials group study. Ann Intern Med 1990;113:111-117
46. Noble S, Faulds D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998:56:115-146
47. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson ÇA, et al (AIDS Clinical Trials Group and Cytomegalovirus Coopérative Study Group). A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993:168:557-563
48. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al (Syntex Cooperative Oral Ganciclovir Study Group). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl 1 Med 1995:333:615620
49. Merigan TC, Renlund DG, Keay S, Brlstow MR, Starnes V, O'Connell JB, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992:326:1182-1186
50. Goodrich JM, Mori M, Cleaves CA, Du Mond C, Cays M, Ebeling OF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-1607
51. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993:118:173-178
52. Gane E, Sallba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al (Oral Ganciclovir International Transplantation Study Group). Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [published erratum appears in Lancet 1998;351:454). Lancet 1997:350:1729-1733
53. Emanuel D, Cunningham I, Jules-Elysée K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988:109:777-782
54. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treat ment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988:109:783-788
55. Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother 1996:37:303-313
56. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R (Topical Penciclovir Collaborative Study Group). Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA 1997;277: 1374-1379
57. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellers J, Shafran SD (Canadian Famciclovir Study Group). Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, doubleblind multicenter trial. JAMA 1996:276:44-49
58. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL (Collaborative Famciclovir Genital Herpes Research Group). Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998:280:887-892
59. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al (Collaborative Famciclovir Herpes Zoster Study Group). Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995:123:8996
60. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tal DI, et al (Asia Hepatitis Lamivudine Study Group). A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998:339:61-68
61. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998:28:585-589
62. Lea AP, Bryson HM. Cidofovir. Drugs 1996:52:225-230
63. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997:126:257-263
64. Studies of Ocular Complications of AIDS Research Group in Collaboration With the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial: a randomized, controlled trial. Ann Intern Med 1997:126:264-274
65. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report. Ann Intern Med 1996:125:98-103
66. Kirsi JJ, North JA, McKernan PA, Murray BK, Canonico PG, Muggins JW, et al. Broad-spectrum antiviral activity of 2-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983:24:353-361
67. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985:254:3047-3051
68. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. N Engl J Med 1983:308:1443-1447
69. Smith DW, Frankel LR, Mathers LH, Tang ATS, Arlagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991:325:24-29
70. Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 1994:22:566-572
71. Moler FW, Steinhart CM, Ohmit SE, Stldham GL (Pédiatrie Critical Study Group). Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr 1996:128:422-428
72. American Academy of Pediatrics. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village (IL): American Academy of Pediatrics; 1997. pp 444-447
73. Guglielmo BJ, Jacobs RA, Locksley RM. The exposure of health care workers to ribavirin aerosol [letter]. JAMA 1989:261:18801881
74. Centers for Disease Control. Assessing exposures of health-care personnel to aerosols of ribavirin-California. MMWR Morb Mortal WklyRep 1988:37:560-563
75. Bradley JS, Connor JD, Compogiannis LS, Eiger LL. Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections. Antimicrob Agents Chemother 1990:34:668670
76. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al (International Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998:339:14931499
77. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, et al (Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998:339:14851492
78. Holmes GP, McCormick JB, Track SC, Chase RA, Lewis SM, Mason ÇA, et al. Lassa fever in the United States: investigation of a case and new guidelines for management. N Engl J Med 1990;323: 1120-1123
79. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui Jl. Canonico PG. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 1987:7:353-359
80. Alrabiah FA, Sacks SL. New antiherpesvirus agents: their targets and therapeutic potential. Drugs 1996:52:17-32
81. Studies of Ocular Complications of AIDS Research Group in Collaboration With the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996:114:2333
82. Erlich KS. Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. W Engl J Med 1989; 320:293-296
83. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47(RR-6):l-26
84. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, WebberJones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982:307:580-584
85. Waghorn SL, Goa KL. Zanamivir. Drugs 1998:55:721-725
86. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al (GG167 Influenza Study Group). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997:337:874-880
87. MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections [published errata appear in Lancet 1999:353:504 and 1999;353:1104). Lancet 1998:352:1877-1881
88. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999:282:31-35
89. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 1998:56:537-553
90. Hayden F, Treanor JJ. Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999:282:1240-1246
91. Eron U, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986; 315:1059-1064
92. Reichman RC, Oakes D, Bonnez W. Greisberger C, Tyring S, Miller L, et al. Treatment of condyloma acuminatum with three different interferons administered intralesionally: a double-blind, placebocontrolled trial. Ann Intern Med 1988:108:675-679
93. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant Interferon alfa-2a: a multicenter double-blind placebo-controlled clinical trial. JAMA 1991:265:2684-2687
94. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with Interferon alfa for chronic hepatitis B. N Engl J Med 1996:334: 1422-1427
95. Gaudreau A, Hill E, Balfour HH Jr, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998:178: 297-303
96. Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990:112:187191
97. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999;12:286-297
98. Erice A, Gil-Roda C, Perez JL, Balfour HH Jr, Sannerud KJ, Hanson MN, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997:175:1087-1092
99. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989:159:430-435
100. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immuno compromised adults. Clin Infect Dis 1998:26:1418-1424
101. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992:176:119-130
102. Groarke JM, Pevear DC. Attenuated virulence of pleconaril-resistant coxsackievirus 63 variants. J Infect Dis 1999:179:1538-1541
103. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997:10:674-693
104. Neyts J, De Clercq E. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [lR(la,2.3a)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. Transplantation 1999:67:760-764